IgA nephropathy therapeutics market seen topping $1.9 billion by 2030

The global market for IgA nephropathy therapies is projected to rise from $1.09 billion in 2025 to $1.91 billion by 2030, driven by more kidney disease diagnoses, biologics and complement inhibitors. North America leads now, while Asia-Pacific is expected to grow fastest as screening, clinical trials and renal drug pipelines expand.

Why it matters: - The IgA nephropathy therapeutics market is growing alongside the broader burden of chronic kidney disease, which increases demand for treatments that can slow kidney damage and reduce proteinuria. - The market outlook points to stronger adoption of precision medicine, biologics and complement inhibitors, which could change how the kidney disorder is treated over the next several years.

What happened: - The Business Research Company said the global IgA nephropathy therapeutics market is projected to increase from $1.09 billion in 2025 to $1.21 billion in 2026. - The report puts the market at $1.91 billion by 2030, with a forecast CAGR of 12.0%. - The company published the outlook on July 17, 2026, in London. - The report includes a free sample at the sample request page and the full report at the market report page.

The details: - Historical growth was driven by higher chronic kidney disease prevalence, more awareness of IgA nephropathy diagnosis, wider use of corticosteroids and immunosuppressants, better renal biopsy and diagnostic tools, and higher healthcare spending on nephrology. - IgA nephropathy therapeutics are pharmaceutical and biologic treatments designed to reduce inflammation, slow disease progression, manage proteinuria and preserve kidney function. - The market’s expected growth drivers include precision medicine, biomarker-based treatments, broader use of biologic drugs and complement inhibitors, more clinical trials, expanded early screening programs and higher investment in renal drug development. - Key trends highlighted in the report include complement-inhibition therapies, monoclonal antibodies for immune-related kidney inflammation, biomarker-driven patient stratification, oral small molecules to reduce proteinuria, and drug-delivery systems designed to improve sustained targeting. - In 2025, North America held the largest share of the market. - The Asia-Pacific region is expected to grow fastest in the coming years because of improving healthcare infrastructure and rising awareness. - The regional analysis also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The report says its 2026 editions include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel dashboards, market hotspots infographics, and updated technology and future-trend analysis.

Between the lines: - The forecast suggests IgA nephropathy is moving from a largely managed kidney condition toward a more targeted drug-development field. - Growth in screening and diagnostics should expand the patient pool being identified for treatment, while the rise of biologics and complement inhibitors points to a more specialized competitive landscape. - The report’s emphasis on biomarkers and precision medicine signals that future market leadership may depend on therapies that can better segment patients and show clearer clinical benefit.

What's next: - More clinical trials in IgA nephropathy are likely to shape the next wave of treatment options. - Expanded early screening for kidney disease could lift diagnosis rates and increase demand for therapies. - Investment in renal drug pipelines is expected to keep rising as companies pursue oral small molecules, biologics and complement-targeted approaches. - The company’s report positions North America as the current market leader and Asia-Pacific as the fastest-growing region to watch.